Johnson & Johnson (JNJ) Offers 2% Yield, Projects 8.2% Earnings Growth
Published on · Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowJohnson & Johnson (JNJ) has a forward dividend yield of approximately 2% and has raised its quarterly cash payout for 65 years, averaging annual increases of 5.7% over the last decade. The company anticipates earnings growth of 8.2% in 2026 and 9.8% in 2027. Key drivers include a recently announced $5.5 billion settlement regarding talc product liabilities and a 73% sales growth in its Tremfya psoriasis treatment, generating $2 billion in revenue. This projected earnings growth supports potential for further dividend increases, making JNJ attractive for dividend-focused investors.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Johnson & Johnson (JNJ)
Johnson & Johnson is a healthcare giant spanning pharmaceuticals and medical devices, known for its deep drug pipeline.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier JNJ news
- XLV vs PBE: Comparing Two Healthcare ETFs for Investors
- Coca-Cola (KO) and Johnson & Johnson Big Premarket Moves
- Johnson & Johnson (JNJ) Settles Talc Lawsuits for $5.5 Billion
- Realty Income (O) Offers 5.11% Yield With 670 Consecutive Dividends
- Social Security at 62 Reduces Benefits by 30%; Dividend Strategies Impact Wealth
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
